4-
10
B-Borono-2-
18
F-fluoro-
l
-phenylalanine (
18
F-FBPA) was developed for monitoring the pharmacokinetics of 4-
10
B-borono-
l
-phenylalanine (
10
B-BPA) used in boron neutron capture therapy (BNCT) with positron emission tomography (PET). The tumor-imaging potential of
18
F-FBPA was demonstrated in various animal models. Accumulation of
18
F-FBPA was higher in melanomas than in non-melanoma tumors in animal models and cell cultures.
18
F-FBPA was incorporated into tumors mediated mainly by L-type amino acid transporters in in vitro and in vivo models. Tumoral distribution of
18
F-FBPA was primarily related to the activity of DNA synthesis.
18
F-FBPA is metabolically stable but is incorporated into melanogenesis non-enzymatically. These in vitro and in vivo characteristics of
18
F-FBPA corresponded well to those of
10
B-BPA. Nuclear magnetic resonance and other studies using non-radioactive
19
F-
10/11
B-FBPA also contributed to characterization. The validity and reliability of
18/19
F-FBPA as an in vivo probe of
10
B-BPA were confirmed by comparison of the pharmacokinetics of
18
F-FBPA and
10
B-BPA and direct measurement of both
18
F and
10
B in tumors with various doses of both probes administered by different routes and methods. Clinically, based on the kinetic parameters of dynamic
18
F-FBPA PET, the estimated
10
B-concentrations in tumors with continuous
10
B-BPA infusion were similar to those measured directly in surgical specimens. The significance of
18
F-FBPA PET was verified for the estimation of
10
B-concentration and planning of BNCT. Later
18
F-FBPA PET has been involved in
10
B-BPA BNCT of patients with intractable tumors such as malignant brain tumors, head and neck tumors, and melanoma. Usually a static PET scan is used for screening patients for BNCT, prediction of the distribution and accumulation of
10
B-BPA, and evaluation of treatment after BNCT. In some clinical trials, a tumor-to-normal tissue ratio of
18
F-FBPA > 2.5 was an inclusion criterion for BNCT. Apart from BNCT,
18
F-FBPA was demonstrated to be a useful PET probe for tumor diagnosis in nuclear medicine: better tumor-to-normal brain contrast compared with
11
C-methionine, differentiation of recurrent and radiation necrosis after radiotherapy, and melanoma-preferential uptake. F...